'''Aplaviroc''' ([[International Nonproprietary Name|INN]], codenamed '''AK602''' and '''GSK-873140''') is a [[CCR5]] [[entry inhibitor]] that belongs to a class of [[2,5-Diketopiperazine|2,5-diketopiperazines]]<ref>{{Cite journal | title = 2,5-Diketopiperazines: Synthesis, Reactions, Medicinal Chemistry, and Bioactive Natural Products | author = Borthwick AD | journal = Chemical Reviews | year = 2012 | volume = 112 | issue = 7 | pages = 3641–3716 | doi = 10.1021/cr200398y | pmid = 22575049}}</ref> developed for the treatment of [[HIV]] infection.<ref>{{cite web |url=http://www.retroconference.org/2004/cd/PDFs/540.pdf |title=Determination of binding sites of a unique CCR5 inhibitor AK602 / ONO-4128/ GW873140 on human CCR5 |first1=Kenji |last1=Maeda |first2=Hiromi |last2=Ogata |first3=Shigeyoshi |last3=Harada |first4=Toshikazu |last4=Miyakawa |first5=Hirotomo |last5=Nakata |first6=Yasuhiro |last6=Koh |first7=Yasushi |last7=Tojo |first8=Shiro |last8=Shibayama |first9=Yoshikazu |last9=Takaoka |first10=Kenji |last10=Sagawa |first11=Fukushima |last11=Daikichi |first12=Joseph |last12=Moravek |first13=Edward |last13=Arnold |first14=Hiroaki |last14=Mitsuya |display-authors=3 |archiveurl=https://web.archive.org/web/20051103110511/http://www.retroconference.org/2004/cd/PDFs/540.pdf |format=PDF |archivedate=November 3, 2005 |year=2004 |publisher=[[Conference on Retroviruses and Opportunistic Infections]] |deadurl=yes }}</ref><ref>{{cite journal |url=http://jvi.asm.org/cgi/content/abstract/79/4/2087 |title=Potent Anti-R5 Human Immunodeficiency Virus Type 1 Effects of a CCR5 Antagonist, AK602/ONO4128/GW873140, in a Novel Human Peripheral Blood Mononuclear Cell Nonobese Diabetic-SCID, Interleukin-2 Receptor γ-Chain-Knocked-Out AIDS Mouse Model |first1=Hirotomo |last1=Nakata |first2=Kenji |last2=Maeda |first3=Toshikazu |last3=Miyakawa |first4=Shiro |last4=Shibayama |first5=Masayoshi |last5=Matsuo |first6=Yoshikazu |last6=Takaoka |first7=Mamoru |last7=Ito |first8=Yoshio |last8=Koyanagi |first9=Hiroaki |last9=Mitsuya |display-authors=3 |volume=79 |issue=4 |pages=2087–96 |date=February 2005 |journal=Journal of Virology |doi=10.1128/jvi.79.4.2087-2096.2005 |pmid=15681411 |pmc=546550}}</ref> It was developed by [[GlaxoSmithKline]].
